Drugs / Canrenoate
Canrenoate
also known as
Potassium Canrenoate · Acide canrenoique · Acido canrenoico · Canrenoate de potassium · Canrenoate Potassium · Canrenoato de potasio · Canrenone free acid potassium salt · Kanrenol · +5 more
Small molecule targets NR3C2 via inhibition
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04977960 | Sep 2022 → May 2023 | acute respiratory distress syndrome | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Unknown | No outcome recorded |
| Phase 2 | NCT04714710 | Aug 2021 → Dec 2023 overdue | — | Pr. Nicolas GIRERD | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01059136 | Feb 2010 → Aug 2014 | myocardial infarction | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05411991 | Jun 2022 → Jul 2024 | heart failure | Vrije Universiteit Brussel | Completed | No outcome recorded |
| Phase 4 | NCT04912011 | Jan → Aug 2021 | pneumonia | Pomeranian Medical University Szczecin | Unknown | No outcome recorded |
| Phase 4 | NCT00741663 | Apr 2005 → Sep 2008 | cirrhosis of liver | University of Padova | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01882179 Comparator | Nov 2013 → May 2016 | ST-elevation myocardial infarction | University College, London | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04062760 Background | Dec 2019 → Dec 2021 | heart failure | University of Parma | Unknown | No outcome recorded |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Canrenoate | “Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months” NCT01059136 ↗ |
| Known as | Acide canrenoique | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Known as | Acido canrenoico | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Known as | Canrenoate de potassium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Known as | Canrenoate Potassium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04912011 ↗ |
| Known as | Canrenoato de potasio | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Known as | Canrenone free acid potassium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Known as | Kanrenol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Known as | NSC-757789 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Known as | Potassium Canrenoate | “a single intravenous bolus of potassium canrenoate (200 mg) followed by oral spironolactone (25 mg once daily) for 6 months in addition to standard therapy or standard therapy alone” PMID 27102506 ↗ Apr 20165“Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.” NCT04062760 ↗ “The sequential treatment provided potassium canrenoate at the initial dose of 200 mg/day, then increased to 400 mg/day.” PMID 19570764 ↗ Jan 2010 |
| Known as | SC-14266 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Known as | Soldactone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Known as | Soldactone (brand name for canrenoate) | “Soldactone (brand name for canrenoate)” NCT05411991 ↗ |
| Known as | Spiroctan-m | ChEMBL registry synonym — accepted as the source's own label CHEMBL1616951 ↗ |
| Action | Inhibit | “Mineralocorticoid receptor antagonist potassium-canrenoate” NCT01882179 ↗1“Mineralocorticoid receptor antagonist” CHEMBL1616951 ↗ |
| Modality | Small molecule | — CHEMBL1616951 ↗ |
| Route | Intravenous | “Unique 200mg IV dose of Potassium Canrenoate” NCT01059136 ↗ |
| Target | NR3C2 | “Mineralocorticoid receptor antagonist” CHEMBL1616951 ↗ |